Augustine Therapeutics

Series-A
augustinetx.com Biotech & Healthcare
Total Funding Undisclosed
Latest Round Undisclosed Series-A
Last Announced Mar 24, 2025
Investors Undisclosed
Decision Makers 6 Verified

About Augustine Therapeutics

Augustine Therapeutics is developing selective, safe and efficacious HDAC6 inhibitors designed for treatment of neuromuscular, neurodegenerative and cardiometabolic diseases. Discover our pipeline poised for clinical impact.

Sectors & Market Categories

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-A
Global Headquarters Undisclosed
Tracked Since Oct 1, 2026

Web & Domain Identity

Official Website augustinetx.com
Domain Registered Date Undisclosed

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Not linked

Company Milestones & Timeline

2 Events
  1. Capital Raise

    Series-A announced

    fundraisingfox.com

  2. Capital Raise

    Series-A announced

    fundraisingfox.com

Investors & Backers

Investor firms and individual backers were not publicly disclosed in available round filings for Augustine Therapeutics.

Funding History

2 Rounds
Series-A · Mar 24, 2025
Series-A · Jun 26, 2024

Founders & Leadership

1

Ludo Van Den Bosch

Scientific founder and Chairman of the Advisory Board

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

START FREE WITH 50 CREDITS
Recently funded startups
New SaaS launches
Never pay twice for contacts